Latest On KemPharm, Inc (KMPH):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-03 22:38 EST | News | KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating | N/A |  |
| 2022-12-21 23:58 EST | News | KemPharm starts phase 2 trial of sleep disorder therapy KP1077 | N/A | |
| 2022-11-18 16:26 EST | News | FDA awards Orphan Drug Designation to Kempharm for idiopathic hypersomnia candidate | N/A | |
| 2022-11-10 01:56 EST | News | KemPharm GAAP EPS of -$0.19 misses by $0.03, revenue of $2.87M misses by $0.14M | N/A | |
| 2022-11-10 01:56 EST | News | KemPharm down 5% after Q3 results miss on both lines | N/A | |
About KemPharm, Inc (KMPH):
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the compan read more...y has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
General
- Name KemPharm, Inc
- Symbol KMPH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 22
- Last Split Factor1:16
- Last Split Date2020-12-28
- Fiscal Year EndDecember
- IPO Date2015-04-16
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://kempharm.com
Valuation
- Forward PE 5.18
- Price/Sales (Trailing 12 Mt.) 2.73
- Enterprise Value Revenue 20.47
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $1.26
- Next Year EPS Estimate $0.14
- Next Quarter EPS Estimate $2.54
- Profit Margin -96%
- Operating Margin -36%
- Return on Assets -28%
- Revenue 13.29 million
- Earnings Per Share -$1.73
- Revenue Per Share $3.34
- Gross Profit 11.98 million
- Quarterly Earnings Growth 71.9%
Highlights
- Market Capitalization 319.52 million
- EBITDA -44440000
- Analyst Target Price $26
- Book Value Per Share -$2.83
Share Statistics
- Shares Outstanding 28.38 million
- Shares Float 27.5 million
- % Held by Insiders 712%
- % Held by Institutions 6.03%
- Shares Short 2.98 million
- Shares Short Prior Month 2.31 million
- Short Ratio 0.87
- Short % of Float 16%
- Short % of Shares Outstanding 16%
Technicals
- Beta 3.26
- 52 Week High $22.08
- 52 Week Low $1.94
- 50 Day Moving Average 9.27
- 200 Day Moving Average 10.64
Dividends
- Dividend Date 2020-12-28
- ExDividend Date N/A
- Dividend Yield 0%
KemPharm, Inc (KMPH) Dividend Calendar:
KMPH's last dividend payment was made to shareholders on December 28, 2020.
KemPharm, Inc (KMPH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
KemPharm, Inc (KMPH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
KemPharm, Inc (KMPH) Chart:
KemPharm, Inc (KMPH) News:
Below you will find a list of latest news for KemPharm, Inc (KMPH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
KemPharm, Inc (KMPH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest KMPH Trades:
KemPharm, Inc (KMPH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-30 | 8-K/A (Current report) | |
| 2020-10-30 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-29 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-26 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-10-26 | 8-K (Current report) | |
| 2020-10-08 | DEF 14A (Other definitive proxy statements) | |
| 2020-09-25 | PRE 14A (Other preliminary proxy statements) | |
| 2020-09-25 | 8-K (Current report) | |
| 2020-09-25 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-26 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 8-K (Current report) | |
| 2020-08-12 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-11 | 25-NSE (Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret) | |
| 2020-07-17 | 8-K (Current report) | |
| 2020-06-24 | 8-K (Current report) | |
| 2020-06-24 | 8-K (Current report) | |
KemPharm, Inc (KMPH) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of KemPharm, Inc (KMPH). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 712%
Institutional Ownership: 603%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-26 | R. LaDuane Clifton | CFO, Secretary & Treasurer | Buy | 1,000.00 | 0.84 | 839.00 | 50,000.00 | |
| 2020-08-18 | David S Tierney | Director | Buy | 2,500.00 | 0.64 | 1,606.75 | 21,872.00 | |
| 2020-08-18 | David S Tierney | Director | Buy | 2,000.00 | 0.65 | 1,290.00 | 23,872.00 | |
| 2020-08-18 | Richard W Pascoe | Director | Buy | 7,200.00 | 0.63 | 4,564.80 | 25,773.00 | |
| 2020-08-18 | Richard W Pascoe | Director | Buy | 1,000.00 | 0.64 | 635.00 | 26,773.00 | |
| 2020-08-18 | David S Tierney | Director | Buy | 4,500.00 | 0.66 | 2,970.00 | 28,372.00 | |
| 2020-08-18 | Richard W Pascoe | Director | Buy | 1,800.00 | 0.64 | 1,152.00 | 28,573.00 | |
| 2020-08-18 | David S Tierney | Director | Buy | 1,000.00 | 0.67 | 665.00 | 29,372.00 | |
| 2020-08-18 | R. LaDuane Clifton | CFO, Secretary & Treasurer | Buy | 2,000.00 | 0.70 | 1,390.00 | 49,000.00 | |
| 2020-06-11 | R. LaDuane Clifton | CFO, Secretary & Treasurer | Buy | 1,500.00 | 0.19 | 288.45 | 47,000.00 | |
| 2020-06-02 | Travis C Mickle | President & CEO | Buy | 110,000.00 | 0.19 | 20,790.00 | 1,888,117.00 | |
| 2020-05-26 | R. LaDuane Clifton | CFO, Secretary & Treasurer | Buy | 11,500.00 | 0.18 | 2,104.50 | 45,500.00 | |
| 2020-03-25 | R. LaDuane Clifton | CFO, Secretary & Treasurer | Buy | 1,000.00 | 0.22 | 218.20 | 34,000.00 | |
| 2020-03-13 | Timothy J. Sangiovanni | VP, Corporate Controller | Buy | 4,000.00 | 0.20 | 800.00 | 18,000.00 | |
| 2020-03-11 | R. LaDuane Clifton | CFO, Secretary & Treasurer | Buy | 8,000.00 | 0.25 | 2,010.40 | 33,000.00 | |
| 2020-03-10 | Timothy J. Sangiovanni | VP, Corporate Controller | Buy | 7,657.00 | 0.26 | 1,952.54 | 14,000.00 | |
| 2020-03-10 | Timothy J. Sangiovanni | VP, Corporate Controller | Buy | 10.00 | 0.25 | 2.53 | 6,343.00 | |
| 2020-03-09 | Timothy J. Sangiovanni | VP, Corporate Controller | Buy | 333.00 | 0.25 | 83.25 | 6,333.00 | |
| 2020-03-05 | Travis C Mickle | President & CEO | Buy | 3,000.00 | 0.33 | 1,003.20 | 1,756,117.00 | |
| 2020-03-05 | Travis C Mickle | President & CEO | Buy | 3,000.00 | 0.33 | 1,002.30 | 1,759,117.00 | |